Corpus Intelligence IC Memo — BAYSHORE MEDICAL CENTER 2026-04-26 04:03 UTC
IC Memo — BAYSHORE MEDICAL CENTER
Investment Committee Memorandum | NJ | 175 beds | Grade C | EBITDA uplift $13.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BAYSHORE MEDICAL CENTER

CCN 310112 | MONMOUTH, NJ | 175 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BAYSHORE MEDICAL CENTER is a 175-bed suburban community hospital in MONMOUTH, NJ with $186.7M in net patient revenue and a 2.1% operating margin. The hospital serves a payer mix of 44.3% Medicare, 1.8% Medicaid, and 53.9% commercial.

Thesis: Undervalued. Our ML models identify $13.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.1% to 9.5% (+736bps).

Net Revenue HCRIS$186.7M
Current EBITDA COMPUTED$4.0M
Operating Margin COMPUTED2.1%
Occupancy HCRIS55.6%
Revenue / Bed COMPUTED$1.1M
Net-to-Gross HCRIS21.0%
Distress Probability ML46.4%

2. Market Context & Competitive Position

95
NJ Hospitals
-3.9%
State Median Margin
52
Comparable Hospitals

NJ has 95 Medicare-certified hospitals with a median operating margin of -3.9%. The target's margin of 2.1% places it above the state median. Among 52 size-comparable peers (88-350 beds), the median margin is -3.5%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (88-350), prioritizing same-state peers. 52 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BAYSHORE MEDICAL CENTER (Target)NJ175$186.7M2.1%
ENGLEWOOD HOSPITAL & MED CTRNJ292$967.3M0.1%
CAPITAL HEALTH MED CENTER - HONJ209$746.8M0.8%
PRINCETON HEALTHCARE SYSTEMNJ206$587.8M-5.7%
INSPIRA MEDICAL CENTER VINELANNJ280$505.5M-12.0%
HOLY NAME HOSPITALNJ289$493.4M8.1%
HMH -OCEAN UNIVERSITY MEDICAL NJ329$466.2M-3.9%
JERSEY CITY MEDICAL CENTERNJ289$456.8M-13.7%
MONMOUTH MEDICAL CENTERNJ240$448.7M-10.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $13.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.9M+210bp18mo
Cost to Collect4.5%2.5%$3.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.3M+122bp9mo
Clean Claim Rate88.0%96.0%$119K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.9M
Cost to Collect
$3.7M
Denial Rate Reduction
$3.7M
A/R Days Reduction
$2.3M
Clean Claim Rate
$119K
Total EBITDA Uplift$13.7M
Current EBITDA$4.0M
+ RCM Uplift+$13.7M
Pro Forma EBITDA$17.7M
Current Margin2.1%
Pro Forma Margin9.5%
WC Released (1x)$7.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$6.1M$163.8M26.67x92.8%
Base (11x exit)10.0x11.0x$6.1M$182.1M29.66x97.0%
Bull Case9.0x11.0x$5.5M$229.5M41.52x110.7%
Bull (12x exit)9.0x12.0x$5.5M$252.0M45.59x114.7%
Bear Case11.0x10.0x$6.8M$93.0M13.78x69.0%
Bear (11x exit)11.0x11.0x$6.8M$104.5M15.48x73.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 52 hospitals with 88-350 beds
  • Same-state prioritization (n=53)
  • Comp margins: P25=-19.0% / P50=-3.5% / P75=2.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.